Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Xenogen, Biogen Collaborate on In Vivo Imaging
May 2003
ALAMEDA, Calif., May 22 -- Xenogen Corp. announced today it has entered into an agreement with Biogen Inc. to evaluate Xenogen's proprietary real-time in vivo imaging technology in their discovery research programs. This technology is expected to enhance the efficiency of Biogen's drug discovery efforts.

Under the terms of the agreement, Biogen is licensed to practice Xenogen's real-time in vivo imaging technology, using Xenogen's IVIS imaging system and Living Image software package, and will receive access to some of Xenogen's Bioware cells and in-vivo models.

Xenogen's real-time in vivo imaging technology platform is in use at biotechnology and pharmaceutical companies and academic laboratories. Research applications include enhancing drug discovery and development through the use of more predictive and physiologically relevant in vivo systems earlier in the drug development cycle than was previously possible, enabling researchers to better understand diseases.

Xenogen's IVIS system is an ultrasensitive camera used with proprietary hardware and Living Image software to noninvasively detect, quantify and manage emitted light from within a living animal; from Bioware cells and microorganisms -- tumor cell lines, bacteria and fungi modified to emit light; and from in-vivo models -- bioluminescent in-vivo models that emit light when target genes are active.

For more information, visit:

BiogenBioware cellsin vivo imagingin-vivo modelsIvisLiving ImageNews & FeaturesXenogen

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.